Reboot: REmote moBile Outpatient mOnitoring in Transplant 2.0

Sponsor
University Health Network, Toronto (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT04721288
Collaborator
(none)
400
2
31

Study Details

Study Description

Brief Summary

This study is designed to determine if an innovative mobile health intervention designed to improve patient-provider communication can reduce unscheduled hospitalizations, and visits to the emergency department and ambulatory clinic in adult heart, liver, and kidney transplant patients.

Condition or Disease Intervention/Treatment Phase
  • Other: Active communication through Reboot application
  • Other: Generic communication through Reboot application
N/A

Detailed Description

Mobile health technologies such as smartphones and wearable devices can remotely monitor health. These technologies hold promise to improve health outcomes in a spectrum of patients by providing health care teams with better connectivity which may prompt more timely responses to questions and improvements to care.

The purpose of this study is to evaluate if solid organ transplant (SOT) recipients benefit from improved monitoring and removal of communication barriers as the most common reasons for readmission and mortality may be mitigated by clinical intervention. Additionally, medication adherence is critical in transplant patients to prevent graft rejection. We anticipate that remote monitoring will improve medication adherence/adjustments, and will allow for identification of early health issues, reducing preventable hospital readmissions. Thus, this study will determine if an innovative mobile health intervention, designed to improve patient-clinician communication, reduces unnecessary hospital readmission and visits to the emergency department and transplant clinic when utilized in addition to the standard of care telephone communication system. We will also incorporate clinical and continuous ambulatory physiologic data collected as part of the mobile health intervention to develop machine learning algorithms capable of identifying early indicators of adverse outcomes in adult heart, kidney, and liver transplant patients.

We hypothesize that: the delivery of personalized communication using a mobile health application will improve patient self-management resulting in a 50% reduction in preventable hospital readmission, and unscheduled visits to the emergency department and transplant clinic. With tailored communication through the mobile health application, we expect fewer standard of care phone messages for patients in the intervention group and patients with higher activity levels (average daily step-count) pre-transplantation will have lower index hospitalization length of stay. Finally, the large dataset collected from this study will allow novel machine learning-derived risk prediction models to more accurately predict adverse outcomes (e.g., organ rejection, infection, and death), compared to conventional regression models.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
400 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Participant)
Primary Purpose:
Prevention
Official Title:
REmote moBile Outpatient mOnitoring in Transplant (Reboot) 2.0
Anticipated Study Start Date :
Dec 1, 2021
Anticipated Primary Completion Date :
Jul 1, 2023
Anticipated Study Completion Date :
Jul 1, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: Intervention Group

1 year of tailored communication with transplant care team through Reboot application in addition to standard of care communication system.

Other: Active communication through Reboot application
Access to active communication with the transplant care team through Reboot application based asynchronous messaging for non-urgent issues, as well as personalized clinical notifications.

Sham Comparator: Standard of Care Group

1 year of generic communication through Reboot application with communication with transplant care team through standard of care communication system.

Other: Generic communication through Reboot application
Access to generic messaging through Reboot application, and communication with the transplant care team through standard of care communication system.

Outcome Measures

Primary Outcome Measures

  1. Unscheduled hospital admission or visit to emergency department or transplant clinic. [1-month]

    A composite score of unscheduled hospital admission, visit to the emergency department or ambulatory transplant clinic (i.e., total number of visits) will be calculated for each group at the pre-specified time intervals. A central adjudication committee will assess each readmission and visit to determine if they constitute a study event.

Secondary Outcome Measures

  1. EuroQol-5 (EQ-5D) Dimension questionnaire [1-month, 3-months, 12-months]

    The EQ-5D is a comprehensive and compact health status classification and health state preference questionnaire, widely used in many patient populations.

  2. Patient-Reported Outcomes Measurement Information System (PROMIS) tool [1-month, 3-months, 12-months]

    PROMIS is a single patient-centered questionnaire that measures and monitors several domains, including physical, mental, and social health. It is validated for use with the general population and individuals living with chronic disease.

  3. Graft survival rate [12-months]

    Transplanted organ survival rate will be calculated for each group at the end of the study period.

  4. Patient survival rate [12-months]

    Patient survival rate will be calculated for each group at the end of the study period.

  5. Easy Call interactions [1-month, 3-months, 12-months]

    The number of interactions that each group has with standard of care communication system ('Easy Call') will be compared.

  6. Index hospitalization length of stay [1-month]

    Participants activity level while on the transplant waiting list will be quantified by their average daily step count, and compared to the length of their index hospitalization.

Eligibility Criteria

Criteria

Ages Eligible for Study:
21 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Solid organ (heart, liver, or kidney) transplant patients

  • The ability to use a smartphone

  • English speaking

Exclusion Criteria:
  • Poor health literacy (reading level less than grade 5)

  • Inability to follow instructions from the Reboot application

  • Transfer to a non-University Health Network Hospital for follow-up and management

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • University Health Network, Toronto

Investigators

  • Principal Investigator: Heather Ross, MD, University Health Network, Toronto

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Heather Ross, Head, Division of Cardiology, University Health Network, Toronto
ClinicalTrials.gov Identifier:
NCT04721288
Other Study ID Numbers:
  • 20-6082.0.1
First Posted:
Jan 22, 2021
Last Update Posted:
Oct 15, 2021
Last Verified:
Oct 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Heather Ross, Head, Division of Cardiology, University Health Network, Toronto

Study Results

No Results Posted as of Oct 15, 2021